Insulet Corporation
Rank #51HypergrowthPODD · Nasdaq · Healthcare
Insulet Corporation (PODD) — Rank #51 by gross profitability (GP/assets 0.61) · ROE 17.4% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001145197 · all metrics point-in-time as of the filing date.
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Show moreShow less
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- insulet.com
Financials
Strengthening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginimproving
- Gross profitabilityimproving
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-18 | 2024-12-31filed 2025-02-21 | 2023-12-31filed 2024-02-23 | 2022-12-31filed 2023-02-24 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 2,708.1 | 2,071.6 | 1,697.1 | 1,305.3 |
| Revenue growth (YoY) | 30.7% | 22.1% | 30.0% | 18.8% |
| Gross profit | 1,939.9 | 1,445.7 | 1,159.9 | 805.6 |
| Gross margin | 71.6% | 69.8% | 68.3% | 61.7% |
| Net income | 247.1 | 418.3 | 206.3 | 4.6 |
| Net margin | 9.1% | 20.2% | 12.2% | 0.4% |
| EPS (diluted) | $3.48 | $5.78 | $2.94 | $0.07 |
| EPS growth (YoY) | -39.8% | 96.6% | 4100.0% | — |
| Cash flow | ||||
| Operating cash flow | 569.3 | 430.3 | 145.7 | 119.0 |
| Capital expenditures | 191.6 | 124.9 | 75.6 | 122.9 |
| Free cash flow | 377.7 | 305.4 | 70.1 | (3.9) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?